Kivizidiale (Timolol, Travoprost)

Timolol blocks beta‑adrenergic receptors in the eye, reducing the production of aqueous humor. Travoprost mimics prostaglandin F2α, increasing the outflow of fluid through the uveoscleral pathway. Together they provide a dual mechanism that effectively lowers eye pressure.

The dosing regimen for Kivizidiale is determined by the prescribing clinician based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) once daily, but exact instructions must come from a qualified eye‑care professional.

Safety data for Kivizidiale in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescribing physician.

To order Kivizidiale, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kivizidiale offers a fixed‑dose combination of a beta‑blocker and a prostaglandin analogue, providing two mechanisms of action in a single bottle. This can simplify treatment compared with using separate timolol and travoprost drops, potentially improving adherence while delivering comparable IOP‑lowering efficacy.

Kivizidiale should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contains particles.

Kivizidiale is applied as an eye drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac of the affected eye(s). Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe allergic reactions, significant drops in heart rate or blood pressure, bronchospasm in patients with respiratory disease, and worsening of glaucoma if IOP is not adequately controlled. Patients should seek immediate medical attention if they experience any of these symptoms.

Kivizidiale is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients, as well as those with severe bronchial asthma, chronic obstructive pulmonary disease, or certain cardiac conduction disorders. It should also be avoided in eyes with active inflammation or infection.